Who founded Traws Pharma?

Traws Pharma was founded by Ramesh Kumar, Ph.D, E. Premkumar Reddy in 1998.

Who are Traws Pharma's investors?

Traws Pharma's investors include OrbiMed.

How much funding has Traws Pharma raised?

Traws Pharma has disclosed $17.3M raised across 4 of its 6 known rounds.

Where is Traws Pharma headquartered?

Traws Pharma is headquartered in Newtown, US.

Traws Pharma

NASDAQ: TRAW

Newtown, US · Founded 1998 · Delaware corporation · 19 employees on LinkedIn · 1 known investors

Find your way into Traws Pharma

Paths you didn't know you had: your email and LinkedIn already hold routes to the Traws Pharma team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Traws Pharma (formerly Onconova Therapeutics) develops investigational antiviral agents targeting respiratory viral infections and certain cancers, with four clinical-stage programs including a cap-dependent endonuclease inhibitor for influenza and bird flu, a protease inhibitor for COVID-19, and two kinase inhibitors for solid tumors and blood cancers.

Biotech

Founders & leadership

Traws Pharma was founded in 1998 by Ramesh Kumar, Ph.D and E. Premkumar Reddy.

Ramesh Kumar, Ph.DCo-founder

E. Premkumar ReddyCo-founder

Manoj ManiarExecutiveExecutive Officer at Onconova Therapeutics

Thomas McKearnExecutive

Ajay BansalCFO2013–2016Ajay Bansal served as CFO at multiple biotech and pharmaceutical companies including Nektar Therapeutics, Lexicon Pharmaceuticals, Complete Genomics, Onconova Therapeutics, and Urovant Sciences, leading IPOs and M&A transactions totaling over $1 billion in capital raised. His background includes roles at Novartis, McKinsey, ZS Associates, and Mehta Partners spanning finance, strategy, business development, and commercial functions.

Steven FruchtmanPresident and CEO2019–2024Steven Fruchtman is President and CEO of Onconova Therapeutics (now Traws Pharma), where he has served for over a decade, and holds a medical background that has informed his leadership of clinical development programs in hematology and oncology.

Iain DukesChief Executive Officer, Secretary and DirectorIain Dukes holds a doctorate in physiology and pharmacology from Oxford University and has held senior roles in pharmaceutical business development and licensing at Merck, Amgen, and GlaxoSmithKline, as well as serving as President and CEO of Essentialis Therapeutics before joining Orbimed as a Venture Partner.

Charles ParkerChief Financial Officer

Nikolay SavchukChief Operating Officer and Director

C. David PauzaChief Science Officer, Virology

Robert R. RedfieldChief Medical Officer

Victor MoyoChief Medical OfficerVictor Moyo serves as Chief Medical Officer at Onconova Therapeutics (now Traws Pharma). He has over two decades of pharmaceutical experience, including prior roles as Chief Medical Officer at OncoPep, Inc. and Executive Vice President and Chief Medical Officer at L.E.A.F. Pharmaceuticals, with expertise in oncology drug development, regulatory submissions, and clinical advancement.

Investors · 1

OrbiMedreportedNew York · $1M – $75M

How we know: funding news · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$17.3M disclosed across 4 of 6 rounds · 2015–2026

▶$50MofferedNov 2026 · 1 investors · Biotechnology

Rule 506(b)